Developed by scientists at Stanford University, Medicenna has exclusively licensed an impressive library of tunable cytokines, we call Superkines. These cytokines include Interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) which are known to be engaged in modulating nearly 2,000 different types of human ailments.
Our Superkines have been engineered to bind to different receptor sub-types with variable specificity and affinity with the additional capacity to tune signaling pathways, cellular responses and cell fate. Further, by fusing Superkines to payloads, antibodies or inactive protein scaffolds, Medicenna is able to generate Empowered Cytokines, Immunokines and long-acting Superkines, respectively, providing additional functionality, targeted delivery and improved pharmacokinetics.
By assembling a repertoire of Visionary Science we are able to orchestrate development of Meaningful Medicines that will provide Infinite Hope to patients.